Compare SKYX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | ADAG |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.3M | 254.4M |
| IPO Year | 2014 | 2020 |
| Metric | SKYX | ADAG |
|---|---|---|
| Price | $1.04 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.00 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 1.1M | 351.3K |
| Earning Date | 05-13-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $25.12 | N/A |
| Revenue Next Year | $24.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.96 | $1.44 |
| 52 Week High | $3.29 | $4.75 |
| Indicator | SKYX | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 32.49 | 42.78 |
| Support Level | $1.05 | $3.49 |
| Resistance Level | $1.27 | $3.53 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 22.15 | 15.71 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.